COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy
Jasmeet Gill, Christopher Hebert, Gates B. Colbert
Abstract
There is a high incidence of acute kidney injury with COVID-19 infections. The etiologies of acute kidney injury could be ischemic acute tubular necrosis or a complex process of complement activation leading to thrombotic microangiopathy. We present a case of 32-year-old Hispanic male with a history of heart transplant, admitted with COVID-19 and atypical hemolytic uremic syndrome, which was successfully treated with Eculizumab.
Topics & Concepts
EculizumabMedicineThrombotic microangiopathyAtypical hemolytic uremic syndromeAcute kidney injuryNephrologyAcute tubular necrosisEtiologyInternal medicineIncidence (geometry)Coronavirus disease 2019 (COVID-19)Complement systemImmunologyGastroenterologyIntensive care medicineKidneyAntibodyInfectious disease (medical specialty)DiseaseOpticsPhysicsComplement system in diseasesCOVID-19 Clinical Research StudiesCOVID-19 Impact on Reproduction